Life Science Nation Newsletter  |  December 11, 2014  |  Issue 92

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Dec. 4 - Dec. 10)

Seeking Global, Seed Stage, Software Enabled Device and HIT Opportunities

Seeking Early Stage 505(b)(2) Therapeutics

Looking for Clinical Stage Devices and Therapeutics
In This Issue

Do You Have the Right Investor List?

Diagnostic Landscape: Imaging and In Vitro Technologies

Panel announcements: Preclinical Investors and Healthcare IT

LSN Videos
RESI 2014, Fenway Park
RESI 3 Family Office Panel
RESI 3 Outbound Fundraising Panel 
RESI 3 Corporate Venture Capital Panel
The Life Science Executive's Fundraising Manifesto
Do You Have the Right Investor List?

By Marlo Galvez, Business Development, LSN


Companies often tell us that they were given a "qualified list" of investors by their investment bank, board, or consultant. And just as often, companies are surprised when LSN staff tell them that from our experience such lists typically have tenuous value, as they're not truly qualified. Recently, a potential client asked us to a review a list of investors that was provided by his investment bank.  One must remember that data comes in two states, out-of-date and very-out-of-date. When an entity boasts about their investor stable or network the most important question is "How up to date is that data?" The next question should be "How many of the investors in your network have current, actionable mandates?" Those questions will quickly separate the real players that truly understand their investor base from those that simply talk a good game.  To prove out the aforementioned point we actually asked for a list and then vetted the list against the LSN investor database and then showed the difference in share numbers that you get when using a real investor database versus a list that isn't curated.  Please read on to get the LSN assessment...


Diagnostic Landscape: Imaging and In Vitro Technologies 

By Shaoyu Chang, MD, MPH,  Senior Research Analyst, LSN 


The global diagnostics market continues to show robust growth, fueled by aging populations and rising awareness of the value of preventive care. In our recent series of articles, we've explored the therapeutic space for cardiovascular diseases, neurology, and oncology. This week, we dive into the diagnostics innovation and investor landscape.

Two major categories stand out in this space: diagnostic imaging devices and in vitro diagnostics (IVD). Diagnostic imaging devices claimed a global market of US$25.7 billion in 2013, with an estimated annual growth rate of 5.7% for the coming six years. More impressively, IVD claimed a US$47.3 billion global market in 2013, with an annual estimated growth rate of 7.3%...

Panel announcements: Preclinical Investors and Healthcare IT

By Tom Crosby, RESI Conference Manager, LSN 


This week, LSN announces two panels for the upcoming Redefining Early Stage Investments Conference: Preclinical and Healthcare IT.


Panel Announcement #1: Preclinical


Moderated by Rajesh Rangantahn, Director of the Office of Translational Research for the NINDS, the audience will hear from:

  • Michael Recny, CEO, Calvert Holdings
  • Natalie Dakers, President and CEO, CDRD
  • David Berry, Partner, Flagship Ventures
  • Ron Demuth, President, Torrey Pines Investments 
Panel Announcement #2: Healthcare IT


Moderated by Randy Scott, Partner, HealthQuest Capital, the audience will hear from:

  • Akhil Saklecha, Partner, Artiman Ventures
  • Rich Simoni, Partner, Asset Management Ventures
  • Rik Vandevenne, Director, River Cities Capital Fund
  • Phillip Sanger, Managing Partner, Texo Ventures...

Address: 9B Hamilton Place, Boston, MA, 02108, USA

Phone: +1 (617) 600-0668


follow us: Follow us on Twitter View our profile on LinkedIn  

Michael Quigley, Director of Research, LSN
Nono Hu, Senior Manager, Branding & Messaging, LSN